Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1CNS 1Breast 1

Conditions

Lung Neoplasms 7Colorectal Neoplasms 4Urinary Bladder Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoid Interstitial Pneumonia 2Leukemia, Lymphocytic, Chronic, B-Cell 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Burkitt Lymphoma 2Brenner Tumor 2Breast Neoplasms 2Adenocarcinoma of Lung 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stomach Neoplasms 1

Interventions

Oxaliplatin 10Leucovorin 9Fluorouracil 9Specimen Handling 6Cetuximab 6Bevacizumab 6Magnetic Resonance Spectroscopy 4pembrolizumab 3cemiplimab 3Pemetrexed 3fludarabine 2dehydroftorafur 2aldesleukin 2Surveys and Questionnaires 2Nivolumab 2Irinotecan 2Immunoglobulin G 2Gemcitabine 2Folfox protocol 2Disulfides 2Cyclophosphamide 2Cisplatin 2Carboplatin 2Biopsy 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tipiracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colonic Neoplasms × Disulfides × 30 days × Clear all
NCT00217737 2026-05-26

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
2,431 enrolled 13 charts
Gastrointestinal

Colonic Neoplasms

NCT02465060 2026-05-26

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡